Cyclophosphamide Injection Usp 1 Gm Shelf Life: 3 Years

Get an overview of CYCLOPHOSPHAMIDE (injection, powder, for solution), including its generic name, formulation (i.e. pill, oral solution, injection, inhaled medicine) and why ita s used. The medication in Cyclophosphamide can be sold under different names.
Refer to the a Also Known Asa section to reference different products that include the same medication as Cyclophosphamide.

Drug Basics
Brand Name: CYCLOPHOSPHAMIDE INJECTION USP 1 GM
Generic Name: CYCLOPHOSPHAMIDE INJECTION USP 1 GM
Drug Type: HUMAN PRESCRIPTION DRUG
Route: ORAL, INTRAVENOUS
Dosage Form: INJECTION, POWDER, FOR SOLUTION

Indications & Usage
Cyclophosphamide for injection is an alkylating drug indicated for treatment of:
a cMalignant Diseases: malignant lymphomas: Hodgkin's disease, lymphocytic lymphoma, mixed-cell type lymphoma, histiocytic lymphoma, Burkitt's lymphoma; multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, adenocarcinoma of ovary, retinoblastoma, breast carcinoma. (1.1)
a cMinimal Change Nephrotic Syndrome in Pediatric Patients: biopsy proven minimal change nephrotic syndrome patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy. (1.2)
Limitations of Use:
The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established.

Malignant diseases
Cyclophosphamide for injection is indicated for the treatment of:
a cmalignant lymphomas (Stages III and IV of the Ann Arbor staging system), Hodgkina s disease, lymphocytic lymphoma (nodular or diffuse), mixed-cell type lymphoma, histiocytic lymphoma, Burkitta s lymphoma
a cmultiple myeloma
a cleukemias: Chronic lymphocytic leukemia, chronic granulocytic leukemia (it is usually ineffective in acute blastic crisis), acute myelogenous and monocytic leukemia, acute lymphoblastic (stem-cell) leukemia (cyclophosphamide for injection given during remission is effective in prolonging its duration)
a cmycosis fungoides (advanced disease)
a cneuroblastoma (disseminated disease)
a cadenocarcinoma of the ovary
a cretinoblastoma
a ccarcinoma of the breast
Cyclophosphamide for injection, although effective alone in susceptible malignancies, is more frequently used concurrently or sequentially with other antineoplastic drugs.
Minimal Change nephrotic Syndrome In Pediatric Patients
Cyclophosphamide for injection is indicated for the treatment of biopsy proven minimal change nephrotic syndrome in pediatrics patients who failed to adequately respond to or are unable to tolerate adrenocorticosteroid therapy.
Limitations of Use:
The safety and effectiveness for the treatment of nephrotic syndrome in adults or other renal disease has not been established.

Adverse Reactions
The following adverse reactions are discussed in more detail in other sections of the labeling.
a cHypersensitivity [see Contraindications (4)]
a cMyelosuppression, Immunosuppression, Bone Marrow Failure, and Infections [see Warnings and Precautions (5.1)]
a cUrinary Tract and Renal Toxicity [see Warnings and Precautions (5.2)]
a cCardiotoxicity [see Warnings and Precautions (5.3)]
a cPulmonary Toxicity [see Warnings and Precautions (5.4)]
a cSecondary Malignancies [see Warnings and Precautions (5.5)]
a cVeno-occlusive Liver Disease [see Warnings and Precautions (5.6)]
a cEmbryo-Fetal Toxicity [see Warnings and Precautions (5.7)]
a cReproductive System Toxicity [see Warnings and Precautions (5.8) and Use in Specific Populations (8.4 and 8.6)]
a cImpaired Wound Healing [see Warnings and Precautions (5.9)]
a cHyponatremia [see Warnings and Precautions (5.10)]